TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.156nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.176nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.202nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.205nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.215nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.289nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.315nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.344nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.359nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.381nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.424nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.435nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.452nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.453nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.494nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 0.5nMAssay Description:The PI3-Kinase biochemical assay was optimized using the HTRF kit provided by Upstate (Millipore). The assay kit contains six reagents: 1) 4× Reactio...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 0.5nMAssay Description:The PI3-Kinase biochemical assay was optimized using the HTRF kit provided by Upstate (Millipore). The assay kit contains six reagents: 1) 4× Reactio...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.504nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.507nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.515nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.517nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.526nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.548nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.563nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.568nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.569nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.585nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.585nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.585nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.598nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 0.600nMAssay Description:The PI3-Kinase biochemical assay was optimized using the HTRF kit provided by Upstate (Millipore). The assay kit contains six reagents: 1) 4× Reactio...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.601nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.620nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.623nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.626nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.642nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.658nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.670nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.675nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.680nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 0.700nMAssay Description:The PI3-Kinase biochemical assays were developed to measure the intrinsic potency and compound dependent inhibition of the alpha, beta, delta, and ga...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataIC50: 0.700nMAssay Description:The PI3-Kinase biochemical assay was optimized using the HTRF kit provided by Upstate (Millipore). The assay kit contains six reagents: 1) 4× Reactio...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.704nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.707nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.753nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.763nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.767nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.774nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.788nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Homo sapiens (Human))
Merck Sharp & Dohme Corp.
US Patent
Merck Sharp & Dohme Corp.
US Patent
Affinity DataIC50: 0.790nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair